7.5. locally-recurrent rcc treatment localised disease. studies reporting local recurrent disease removal kidney considered true definition local recurrence rn, pn thermal ablation, are: local recurrence tumour- bearing kidney, tumour growth exclusively confined true renal fossa, recurrences within renal vein, ipsilateral adrenal gland regional lns. existing literature topic weakly investigated often regarded local recurrent disease. recur protocol-based multicentre european registry capturing patient tumour characteristics, risk recurrence (ror), recurrence patterns, survival curatively treated nonmetastatic rcc 2006 2011. per-protocol resectable disease (rd) recurrence defined (1) solitary metastases, (2) oligometastases, (3) renal fossa renal recurrence radical partial nephrectomy, respectively. within recur consortium, authors assessed effectiveness local treatment resectable recurrent rcc surgical treatment primary kidney tumour . 3039 patients localised rcc treated curative intent, 505 presented recurrence, including 176 rd. patients, 97 underwent local treatment recurrence (ltr) 79 ltr. median os 70.3 mo versus 27.4 ltr versus no-ltr group (p < 0.001). ltr effect survival consistent across risk groups. os hr high, intermediate, low risks 0.36 (0.2-0.64), 0.27 (0.11-0.65), 0.26 (0.08-0.8), respectively. local treatment recurrence associated longer survival across groups risk recurrence 7.5.1. locally-recurrent rcc nephron-sparing approaches locally-recurrent disease affect tumour-bearing kidney pn focal ablative therapy rfa cryotherapy. local relapse may due incomplete resection primary tumour, minority cases local spread tumour microvascular embolisation, true multifocality . prognosis recurrent disease due multifocality poor, despite salvage nephrectomy . recurrent tumour growth regional lns ipsilateral adrenal gland may reflect metachronous metastatic spread (see section 7.3). treatment solely localised disease, systemic progression common . reports minimally invasive approaches (laparoscopic robotic) show atypical reoccurence (e.g. peritoneal, port site, etc) . therefore, specific maneuvers prevent tumour-cell contamination implemented. include use extraction bags, minimising trocar co2 leakage, avoiding tumour morcellation, cleansing instruments reuse, changing gloves tumour extraction, avoiding violation tumor’s natural capsule, cleansing port sites . retrospective study relying inverse probability treatment weighting (iptw) comparing percutaneous ablation (pca) surgical resection (sr) isolated local recurrence (lr) following pn . total 81 patients isolated lr included. percutaneous ablation associated lower risk post-operative complications (odds ratio=0.22; p = 0.006) smaller change egfr. significant differences risk disease, new lr (hr = 1.51; p = 0.59), distant metastasis (hr = 0.19; p = 0.09) . following thermal ablation cryotherapy generally intra-renal, also peri-renal, recurrences reported 14% cases . whereas repeat ablation still recommended preferred therapeutic option treatment failure, effective salvage procedure alternative complete nephrectomy yet defined. 7.5.2. locally-recurrent rcc radical nephrectomy isolated local fossa recurrence rare occurs 1-3% radical nephrectomy. commonly pt3-4 pt1-2 grade iii-iv disease. patients local recurrence rcc diagnosed either ct/mri scans part post-operative follow-up . median time recurrence rn 19-36 months isolated local recurrence 14.5 months group including metastatic cases well [626-628]. isolated local recurrence associated worse survival . based retrospective non-comparative data only, several approaches surgical excision, radiotherapy, systemic treatment observation suggested treatment isolated local recurrence [630-632]. among alternatives, surgical resection negative margins remains therapeutic option shown associated improved survival . open surgery successfully reported studies . one largest series including 2,945 patients treated rn reported 54 patients recurrent disease localised renal fossa, ipsilateral adrenal gland regional lns sole metastatic sites . another series identified 33 patients isolated local recurrences 30 local recurrences synchronous metastases within cohort 2,502 surgically treated patients, confirming efficacy locally directed treatment vs. conservative approaches (observation, systemic therapy) 5-year os isolated local recurrence 60% (95% ci: 0.44-0.73) 10-year os 32% (95% ci: 0.15-0.51). overall survival differed significantly time period primary surgery occurrence recurrence (< 2 years vs. > 2 years: 10-year os rate 31% (95% ci: 10.2-55.0) vs. 45% (95% ci: 21.5-65.8; hr: 0.26; p = 0.0034) . metastatic progression observed 60 patients (58.8%) surgery . patient survival linked type treatment received, shown cohort 96 patients, 45.8% metastatic time recurrence; three-year css rates local recurrence 92.3% ± 7.4%) treated surgery systemic therapy, 63.2% ± 13.2%) underwent surgery, 22.7% ± 0.9%) received systemic therapy 20.5% ± 10.4%) received treatment (p < 0.001) . retrospective multi-centre study patients local retroperitoneal recurrence (rpr) radical nephrectomy (rn) without surgical treatment 2008 2020. retroperitoneal recurrence rcc defined ipsilateral recurrence confined renal fossa, adrenal gland retroperitoneal lymph nodes prior nephrectomy, diagnosed cross-sectional imaging. treatment rpr surgery resulted significantly longer css targeted therapy alone(p < .001). multivariable analysis, high fuhrman grade, size rpr tumour, mixed type rpr, multiple recurrence lesions absence rpr surgery associated significantly increased risk death rcc, suggesting aggressive surgical resection rpr rn represents potentially curative treatment selected rcc patients without synchronous metastases, resulting significantly longer css targeted therapy alone . minimally-invasive approaches, including standard hand-assisted laparoscopic- robotic approaches resection isolated rcc recurrences occasionally reported. large surgical cohort published robotic surgery setting (n = 35) providing standardisation nomenclature, describing surgical technique scenario reporting complications, renal function, oncologic outcomes . ablative therapies including cryoablation, radiofrequency microwave ablation, may also role managing recurrent rcc patients, validation needed . summary, limited available evidence suggests selected patients surgical removal locally- recurrent disease negative margins induce durable tumour control, although expected high risk complications. retrospective review 51 planned repeat pns 47 patients locally-recurrent disease, reporting total 40 peri-operative complications, temporary urinary extravasation prevalent . since local recurrences develop early, median time interval 10-20 months treatment primary tumour , guideline-adapted follow-up scheme early detection recommended (see chapter 8 - follow-up) even though benefit terms cancer control yet demonstrated . adverse prognostic parameters short time interval since treatment primary tumour (< 3-12 months) , sarcomatoid differentiation recurrent lesion incomplete surgical resection . case complete surgical removal unlikely performed significant comorbidities present (especially combined poor prognostic tumour features), palliative therapeutic approaches including radiation therapy aimed symptom control prevention local complications considered (see sections 7.3 7.4). following metastasectomy local recurrence nephrectomy, adjuvant therapy considered (see section 7.2.5. neoadjuvant adjuvant therapy). local recurrence combined metastases treated metastatic rcc. 7.5.3. summary evidence recommendation locally-recurrent rcc treatment localised disease summary evidenceleisolated recurrence nephron sparing procedures nephrectomy rare entity (< 2%).3surgical percutaneous treatment local recurrences absence systemic progression considered, especially absence adverse prognostic parameters favourable performance status.3the optimal modality local treatment locally-recurrent rcc nephron sparing procedures nephrectomy defined.3 recommendationstrength ratingoffer local treatment locally-recurrent disease technically possible balancing adverse prognostic features, comorbidities life expectancy.weak